MSB 2.51% 97.0¢ mesoblast limited

GVHD

  1. 5,344 Posts.
    lightbulb Created with Sketch. 956
    "Based on guidance from the United States Food and Drug Administration (FDA), Mesoblast believes that positive data from this Phase 3 trial may be sufficient for filing for accelerated approval of MSC-100-IV in the United States." What I see here is a vote of confidence of Mesoblast by the FDA Bodes well for future applications !
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.